George Koch

Others, it's going to take a little bit more time, but we're working on it for sure.

But it's that is one place where I think it's it's hard, you know, because you want to be an antibiotic steward.

But on the flip side, you're how do you balance antibiotic stewardship versus sparing skin?

It can be a little bit of a tougher sell there where I'm like, just get the cellulitis better.

Yeah, I like that.

Give me the antibiotics.

Yeah, no, I like that a lot.

We have talked about the fact that a lot of us in reconstructive urology are thinking about these things and the capability is there to do these studies.

Why don't you think more antibiotic practice studies in urology, you know, more prospective antibiotic practice studies in urology are being done?

Yeah.

And that may be helpful to, you know, the next generation sequencing for every patient is not cheap.

You know, things like ERSEP, like it's amazing that they are funding research, but not every, not every trial is going to have, you know, industry funding and being able to potentially model it out.

And it might be a cost-effective way of kind of starting the process, starting the conversation as well.

Yeah, if we're talking about using less antibiotics as opposed to more, it might be tough to get big antibiotics to fund a study.

We've talked a little bit about either urinary microbiome and kind of, I love the idea of shifting it that you mentioned with your trial.

Can you talk a little bit about maybe the history of, you know, we used to consider urine sterile.

Do we still?

I think I know the answer.

And has research in reconstruction and been done with regards to microbiome?

Yeah.